EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS : revenue, balance sheet and financial ratios

EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS is a French company founded 30 years ago, specialized in the sector Gestion d'installations informatiques. Based in VILLERS-BRETONNEUX (80800), this company of category ETI shows in 2024 a revenue of 11.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS (SIREN 403583479)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue 10 956 590 € 10 484 756 € 10 170 004 € 9 893 566 € 9 143 512 € 9 784 940 € 9 872 458 € 10 478 197 € 9 470 145 €
Net income 969 697 € 858 222 € 1 034 406 € 781 577 € 393 841 € 1 635 709 € 522 681 € 566 475 € 752 195 €
EBITDA 1 449 499 € 942 259 € 1 069 998 € 938 245 € 246 803 € 1 208 874 € -54 965 € 555 521 € 639 228 €
Net margin 8.9% 8.2% 10.2% 7.9% 4.3% 16.7% 5.3% 5.4% 7.9%

Revenue and income statement

In 2024, EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS achieves revenue of 11.0 M€. Revenue is growing positively over 9 years (CAGR: +1.8%). Vs 2023: +5%. After deducting consumption (180 k€), gross margin stands at 10.8 M€, i.e. a rate of 98%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 1.4 M€, representing 13.2% of revenue. Positive scissor effect: EBITDA margin improves by +4.2 pts, sign of improved operational efficiency. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 970 k€, i.e. 8.9% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

10 956 590 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

10 776 216 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

1 449 499 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-134 697 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

969 697 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

13.2%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 127%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 13%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.9 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 22.0% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

126.873%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

13.146%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

22.01%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.881

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

11.6%

Solvency indicators evolution
EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS

Sector positioning

Debt ratio
126.87 2024
2022
2023
2024
Q1: 0.0
Med: 9.49
Q3: 56.25
Watch +49 pts over 3 years

In 2024, the debt ratio of EVOLUCARE TECHNOLOGIES ME... (126.87) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.

Financial autonomy
13.15% 2024
2022
2023
2024
Q1: 7.86%
Med: 33.62%
Q3: 54.66%
Average -45 pts over 3 years

In 2024, the financial autonomy of EVOLUCARE TECHNOLOGIES ME... (13.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
0.88 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.17 years
Q3: 1.73 years
Average +11 pts over 3 years

In 2024, the repayment capacity of EVOLUCARE TECHNOLOGIES ME... (0.88) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 95.60. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 6.4x. Operating income very largely covers interest expenses: high safety margin.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

95.6

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

6.444

Liquidity indicators evolution
EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS

Sector positioning

Liquidity ratio
95.6 2024
2022
2023
2024
Q1: 126.5
Med: 180.28
Q3: 285.05
Watch -33 pts over 3 years

In 2024, the liquidity ratio of EVOLUCARE TECHNOLOGIES ME... (95.60) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Interest coverage
6.44x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.26x
Q3: 5.75x
Excellent +25 pts over 3 years

In 2024, the interest coverage of EVOLUCARE TECHNOLOGIES ME... (6.4x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 142 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 321 days. Excellent situation: suppliers finance 179 days of the operating cycle (retail model). Overall, WCR represents 204 days of revenue, i.e. 6.2 M€ to permanently finance.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

6 216 988 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

142 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

321 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

204 j

WCR and payment terms evolution
EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS

Positioning of EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS in its sector

Comparison with sector Gestion d'installations informatiques

Valuation estimate

Based on 362 transactions of similar company sales (all years), the value of EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS is estimated at 2 001 207 € (range 769 411€ - 5 827 851€). With an EBITDA of 1 449 499€, the sector multiple of 1.4x is applied. The price/revenue ratio is 0.20x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
362 transactions
769k€ 2001k€ 5827k€
2 001 207 € Range: 769 411€ - 5 827 851€
NAF 4 all-time Aggregated at NAF sub-class level

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
1 449 499 € × 1.4x
Estimation 2 047 202 €
610 487€ - 7 105 093€
Revenue Multiple 30%
10 956 590 € × 0.20x
Estimation 2 199 609 €
1 080 901€ - 4 680 115€
Net Income Multiple 20%
969 697 € × 1.6x
Estimation 1 588 621 €
699 487€ - 4 356 354€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 362 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Gestion d'installations informatiques)

Compare EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS with other companies in the same sector:

Voir toutes les statistiques du secteur Gestion d'installations informatiques

Frequently asked questions about EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS

What is the revenue of EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS ?

The revenue of EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS in 2024 is 11.0 M€.

Is EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS profitable?

Yes, EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS generated a net profit of 970 k€ in 2024.

Where is the headquarters of EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS ?

The headquarters of EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS is located in VILLERS-BRETONNEUX (80800), in the department Somme.

Where to find the tax return of EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS ?

The tax return of EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS operate?

EVOLUCARE TECHNOLOGIES MEDICAL SOLUTIONS operates in the sector Gestion d'installations informatiques (NAF code 62.03Z). See the 'Sector positioning' section above to compare the company with its competitors.